Table 1

Phase III studies of EGFR-TKI as first-line treatment of patients with EGFR mutated NSCLC

StudyEGFR-TKIChemotherapyMutationMedian PFS (months)RR (%)Median OS (months)
IPASS4GefitinibCarboplatin–paclitaxelAll9.5 vs 6.371.2 vs 47.321.6 vs 21.9
WJTOG34055GefitinibCisplatin–docetaxelL858R
Ex19D
9.2 vs 6.362.1 vs 32.236 vs 39
NEJ0026GefitinibCarboplatin–paclitaxelL858R
Ex19D
10.8 vs 5.473.7 vs 30.727.7 vs 26.6
OPTIMAL7ErlotinibGemcitabine–carboplatinL858R
Ex19D
13.1 vs 4.683 vs 3622.7 vs 28.9
First-Signal8GefitinibGemcitabine–cisplatinAll8.0 vs 6.384.6 vs 37.527.2 vs 25.6
EURTAC9ErlotinibCisplatin–docetaxel/gemcitabineL858R
Ex19D
9.7 vs 5.258 vs 1519.3 vs 19.5
LUX-Lung 310 12AfatinibCisplatin–pemetrexedAll11.1 vs 6.956 vs 2331.6 vs 28.2
LUX-Lung 611AfatinibGemcitabine–cisplatinAll11.0 vs 5.666.9 vs 2323.6 vs 23.511
  • EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; RR, response rate.